Medical cannabis was well tolerated and dropout rate was comparable to those in clinical trials of antidepressant medication. Patients reported a clinically significant reduction of depression severity. Further research on the effectiveness of medical cannabis for MDD seems warranted. Risks of this medication, such as sustaining or inducing a cannabis use disorder, or side effects such as poor concentration, must be taken into consideration.
Keyphrases
- healthcare
- clinical trial
- randomized controlled trial
- end stage renal disease
- major depressive disorder
- systematic review
- depressive symptoms
- newly diagnosed
- ejection fraction
- chronic kidney disease
- sleep quality
- adverse drug
- emergency department
- peritoneal dialysis
- risk assessment
- human health
- physical activity
- bipolar disorder
- combination therapy
- study protocol